[Press News] New Strategic Partnership to Advance Intelligent Organ-on-Chip Technology in Drug Development!
Molecular Devices and Anivance AI Corporation Announce Strategic Partnership to Advance Intelligent Organ-on-Chip Technology in Drug Development Taipei, November 7, 2024 — Molecular Devices, a global leader in life science technologies, and Anivance AI Corporation today announced the signing of a strategic cooperation agreement. Together, they aim to advance the application of intelligent organ-on-chip technology in the biopharmaceutical market, accelerating drug development processes. This collaboration combines expertise in 3D cell culture, high-throughput screening, and organ-on-chip technologies. The goal is to create drug development processes that better mimic human physiological responses, thus improving drug screening efficiency and data analysis. Molecular Devices believes this partnership will expand their capabilities in the Asian market, particularly enhancing high-throughput imaging and data processing to shorten development cycles and increase the success rate of ne...
